Browsing Tag
FDA approval
131 posts
FDA grants accelerated approval to Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Bristol Myers Squibb (NYSE: BMY) has announced a significant breakthrough in the treatment of follicular lymphoma with the…
May 16, 2024
Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration’s…
April 28, 2024
FDA approves Medtronic’s innovative spinal cord stimulator for chronic pain treatment
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced a significant advancement in the treatment…
April 28, 2024
FDA approves Alvotech and Teva Pharmaceuticals’ SELARSDI as biosimilar to Stelara
In a significant development in the pharmaceutical industry, Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of…
April 17, 2024
Bristol Myers Squibb announces success of KRAZATI in Phase 3 KRYSTAL-12 study
Bristol Myers Squibb (NYSE: BMY) has reached a pivotal milestone in the treatment of non-small cell lung cancer…
April 1, 2024
FDA approves Akebia Therapeutics’ Vafseo for anemia in dialysis patients
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients,…
March 28, 2024
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food…
March 24, 2024
LENZ Therapeutics announces merger with Graphite Bio to revolutionize presbyopia treatment
In a significant move for the biopharmaceutical industry, LENZ Therapeutics, Inc. (Nasdaq: LENZ), a trailblazer in developing innovative…
March 24, 2024
FDA approves Italfarmaco’s Duvyzat for duchenne muscular dystrophy treatment
In a significant advancement for the treatment of Duchenne muscular dystrophy (DMD), Italfarmaco S.p.A. has announced the U.S.…
March 24, 2024
FDA approves expansive label updates for Esperion’s NEXLETOL and NEXLIZET
In a significant advancement for heart health management, Esperion (NASDAQ: ESPR) has announced that the United States Food…
March 23, 2024